Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.
Goswami M, Gui G, Dillon LW, Lindblad KE, Thompson J, Valdez J, Kim DY, Ghannam JY, Oetjen KA, Destefano CB, Smith DM, Tekleab H, Li Y, Dagur P, Hughes T, Marté JL, Del Rivero J, Klubo-Gwiezdzinksa J, Gulley JL, Calvo KR, Lai C, Hourigan CS.
Goswami M, et al. Among authors: destefano cb.
J Immunother Cancer. 2022 Jan;10(1):e003392. doi: 10.1136/jitc-2021-003392.
J Immunother Cancer. 2022.
PMID: 35017151
Free PMC article.